PLB-002

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NamePLB-002
Drug Alias NamePLB-002PLB002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN6
TargetsClaudin 6
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsTesticular Neoplasms +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPrimeLink BioTherapeutics
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsTesticular Neoplasms +[4
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A